TQB3909 tablets
Sponsors
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions
Advanced Breast CancerAdvanced Malignant NeoplasmAdvanced Malignant TumorHematologic MalignancyMyelofibrosis
Phase 1
A Clinical Trial of TQB3909 Tablets in Subjects With Advanced Malignant Tumors
NCT04975204
Start: 2022-02-18End: 2024-08-31Target: 126Updated: 2022-03-07
A Clinical Trial of TQB3909 Tablets in Patients With Breast Cancer
NCT05775575
Start: 2023-03-02End: 2023-12-31Target: 65Updated: 2023-03-20
A Study to Evaluate Drug-Drug Interaction of TQB3909 Tablets
NCT06165822
Start: 2023-12-31End: 2024-03-31Target: 40Updated: 2023-12-12
A Clinical Trial of TQB3909 Tablets Combined With TQB3702 Tablets in Patients With Hematologic Malignancy
Not yet recruitingNCT06211751
Start: 2024-01-31End: 2026-06-30Target: 208Updated: 2024-01-18
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
TerminatedNCT06245941
Start: 2024-05-13End: 2025-12-30Updated: 2026-01-05